Summary
Introduction
Transition Therapeutics is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. The company's patented drug discovery technologies have helped the company in expanding its pipeline portfolio.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
The company's clinical pipeline products include: ELND-005 being developed in collaboration with Elan for Alzheimer's disease (Phase II), E1-I.N.T being developed in collaboration with Eli Lilly for diabetes (Phase II), HCV-I.E.T for Hepatitis C (Phase II), and GLP1-I.N.T for diabetes (Phase I). The company recognizes revenues in the form of license fees, collaboration fees and milestone payments. These primarily include revenues recognized from Ellipsis Neurotherapeutics as management fees; milestone payments from Juvenile Diabetes Research Foundation International, Elan and Eli Lilly; and license fees recognized from Novo Nordisk. Transition Therapeutics did not record any revenues during the period 2002-2004. The company's total revenues increased from $0.1 million in 2005 to $0.3 million in 2006. The company derived 100% of its revenues as licensing fees from Novo Nordisk pursuant to its licensing agreement for Transition Therapeutics' I.N.T technology.
Reasons to Purchase
Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization .
|
